Gilead Sciences Inc is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines in areas of unmet medical need, particularly in infectious diseases, oncology, and inflammatory diseases. The company's mission is to advance the care of patients worldwide through groundbreaking research and development. Gilead Sciences Inc employs a strategy focused on leveraging its scientific expertise and robust pipeline to deliver transformative therapies, while also fostering collaborations and partnerships to enhance its operational capabilities and expand access to its life-saving treatments globally.

GILEAD SCIENCES INC

Gilead Sciences is gaining attention in the pharmaceutical sector as it awaits U.S. FDA approval for its new drug, lenacapavir, which targets HIV prevention as a pre-exposure prophylaxis (PrEP). The FDA has accepted Gilead's new drug application, and a decision is expected by June 19, 2025.

Gilead's Lenacapavir Application for Twice-Yearly HIV Prevention Drug Accepted by FDA, Target Approval by June 2025

Gilead Sciences is on the brink of a potential breakthrough with lenacapavir, a twice-yearly injectable that could revolutionize HIV prevention. As the FDA decision looms, can this innovative drug reshape the landscape of HIV treatment and access globally?